Carcinoma, Intraductal, Noninfiltrating: A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.Papilloma, Intraductal: A small, often impalpable benign papilloma arising in a lactiferous duct and frequently causing bleeding from the nipple. (Stedman, 25th ed)Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Adenocarcinoma, Mucinous: An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)Carcinoma, Pancreatic Ductal: Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.Carcinoma, Papillary: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)Adenocarcinoma, Papillary: An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.Carcinoma in Situ: A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).Cystadenoma, Mucinous: A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.Neoplasms, Cystic, Mucinous, and Serous: Neoplasms containing cyst-like formations or producing mucin or serum.Pancreatic Ducts: Ducts that collect PANCREATIC JUICE from the PANCREAS and supply it to the DUODENUM.Carcinoma, Ductal, Breast: An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.Carcinoma, Ductal: Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.Bile Duct Neoplasms: Tumors or cancer of the BILE DUCTS.Nipples: The conic organs which usually give outlet to milk from the mammary glands.Pancreatic Cyst: A true cyst of the PANCREAS, distinguished from the much more common PANCREATIC PSEUDOCYST by possessing a lining of mucous EPITHELIUM. Pancreatic cysts are categorized as congenital, retention, neoplastic, parasitic, enterogenous, or dermoid. Congenital cysts occur more frequently as solitary cysts but may be multiple. Retention cysts are gross enlargements of PANCREATIC DUCTS secondary to ductal obstruction. (From Bockus Gastroenterology, 4th ed, p4145)Pancreatectomy: Surgical removal of the pancreas. (Dorland, 28th ed)Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Liver Neoplasms: Tumors or cancer of the LIVER.Breast Neoplasms: Tumors or cancer of the human BREAST.Neoplasm Invasiveness: Ability of neoplasms to infiltrate and actively destroy surrounding tissue.Cystadenoma, Serous: A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Carcinoma, Basal Cell: A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Cholangiopancreatography, Magnetic Resonance: Non-invasive diagnostic technique for visualizing the PANCREATIC DUCTS and BILE DUCTS without the use of injected CONTRAST MEDIA or x-ray. MRI scans provide excellent sensitivity for duct dilatation, biliary stricture, and intraductal abnormalities.Cystadenocarcinoma, Mucinous: A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)Cyst Fluid: Liquid material found in epithelial-lined closed cavities or sacs.Cholangiopancreatography, Endoscopic Retrograde: Fiberoptic endoscopy designed for duodenal observation and cannulation of VATER'S AMPULLA, in order to visualize the pancreatic and biliary duct system by retrograde injection of contrast media. Endoscopic (Vater) papillotomy (SPHINCTEROTOMY, ENDOSCOPIC) may be performed during this procedure.Cystadenoma, Papillary: A benign neoplasm of the ovary.Endosonography: Ultrasonography of internal organs using an ultrasound transducer sometimes mounted on a fiberoptic endoscope. In endosonography the transducer converts electronic signals into acoustic pulses or continuous waves and acts also as a receiver to detect reflected pulses from within the organ. An audiovisual-electronic interface converts the detected or processed echo signals, which pass through the electronics of the instrument, into a form that the technologist can evaluate. The procedure should not be confused with ENDOSCOPY which employs a special instrument called an endoscope. The "endo-" of endosonography refers to the examination of tissue within hollow organs, with reference to the usual ultrasonography procedure which is performed externally or transcutaneously.Bile Ducts, Intrahepatic: Passages within the liver for the conveyance of bile. Includes right and left hepatic ducts even though these may join outside the liver to form the common hepatic duct.Carcinoma, Lobular: A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Pancreaticoduodenectomy: The excision of the head of the pancreas and the encircling loop of the duodenum to which it is connected.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Neoplasms, Multiple Primary: Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.Bile Ducts, Extrahepatic: Passages external to the liver for the conveyance of bile. These include the COMMON BILE DUCT and the common hepatic duct (HEPATIC DUCT, COMMON).Mucins: High molecular weight mucoproteins that protect the surface of EPITHELIAL CELLS by providing a barrier to particulate matter and microorganisms. Membrane-anchored mucins may have additional roles concerned with protein interactions at the cell surface.Breast: In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.Pancreatic Juice: The fluid containing digestive enzymes secreted by the pancreas in response to food in the duodenum.Carcinoma, Bronchogenic: Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.Carcinoma, Adenoid Cystic: Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)Precancerous Conditions: Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)Gene Expression Regulation, Neoplastic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.Carcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)Cell Line, Tumor: A cell line derived from cultured tumor cells.Carcinoma, Medullary: A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)Cystadenocarcinoma: A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Mucin-2: A gel-forming mucin found predominantly in SMALL INTESTINE and variety of mucous membrane-containing organs. It provides a protective, lubricating barrier against particles and infectious agents.Cystadenoma: A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)Lymphatic Metastasis: Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.Pancreatitis: INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.Pancreas: A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.Carcinoma, Neuroendocrine: A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)Nasopharyngeal Neoplasms: Tumors or cancer of the NASOPHARYNX.Glycodeoxycholic Acid: A bile salt formed in the liver by conjugation of deoxycholate with glycine, usually as the sodium salt. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and choleretic.Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.Common Bile Duct Neoplasms: Tumor or cancer of the COMMON BILE DUCT including the AMPULLA OF VATER and the SPHINCTER OF ODDI.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.DNA, Neoplasm: DNA present in neoplastic tissue.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Salivary Ducts: Any of the ducts which transport saliva. Salivary ducts include the parotid duct, the major and minor sublingual ducts, and the submandibular duct.Biopsy: Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.Endoscopy, Digestive System: Endoscopic examination, therapy or surgery of the digestive tract.Lung Neoplasms: Tumors or cancer of the LUNG.Breast Diseases: Pathological processes of the BREAST.Carcinoma, Mucoepidermoid: A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)Carcinoma, Adenosquamous: A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Carcinoma, Endometrioid: An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.Carcinoma, Embryonal: A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.Mouth Neoplasms: Tumors or cancer of the MOUTH.Exudates and Transudates: Exudates are fluids, CELLS, or other cellular substances that are slowly discharged from BLOOD VESSELS usually from inflamed tissues. Transudates are fluids that pass through a membrane or squeeze through tissue or into the EXTRACELLULAR SPACE of TISSUES. Transudates are thin and watery and contain few cells or PROTEINS.Ampulla of Vater: A dilation of the duodenal papilla that is the opening of the juncture of the COMMON BILE DUCT and the MAIN PANCREATIC DUCT, also known as the hepatopancreatic ampulla.Carcinoma, Merkel Cell: A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)Lithiasis: A condition characterized by the formation of CALCULI and concretions in the hollow organs or ducts of the body. They occur most often in the gallbladder, kidney, and lower urinary tract.Immunoenzyme Techniques: Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.Medical Device Recalls: Removal of a MEDICAL DEVICE from the market due to a problem occurring in the manufacture or distribution of the product.Cholangiocarcinoma: A malignant tumor arising from the epithelium of the BILE DUCTS.Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Adrenocortical Carcinoma: A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.Colonic Neoplasms: Tumors or cancer of the COLON.Carcinoma, Verrucous: A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)Carcinoma, Signet Ring Cell: A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.Mastectomy, Segmental: Removal of only enough breast tissue to ensure that the margins of the resected surgical specimen are free of tumor.Common Bile Duct: The largest bile duct. It is formed by the junction of the CYSTIC DUCT and the COMMON HEPATIC DUCT.Mucin-6: A gel-forming mucin that is predominantly associated with the gastric epithelium.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Loss of Heterozygosity: The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.Neoplasm Grading: Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.Tumor Suppressor Protein p53: Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Carcinoma, Acinar Cell: A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)Stomach Neoplasms: Tumors or cancer of the STOMACH.Mixed Tumor, Malignant: A malignant tumor composed of more than one type of neoplastic tissue. (Dorland, 27th ed)Skin Neoplasms: Tumors or cancer of the SKIN.Reverse Transcriptase Polymerase Chain Reaction: A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.Pancreatic Diseases: Pathological processes of the PANCREAS.Pancreatitis, Chronic: INFLAMMATION of the PANCREAS that is characterized by recurring or persistent ABDOMINAL PAIN with or without STEATORRHEA or DIABETES MELLITUS. It is characterized by the irregular destruction of the pancreatic parenchyma which may be focal, segmental, or diffuse.Mice, Nude: Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.Smad4 Protein: A signal transducing adaptor protein and tumor suppressor protein. It forms a complex with activated RECEPTOR-REGULATED SMAD PROTEINS. The complex then translocates to the CELL NUCLEUS and regulates GENETIC TRANSCRIPTION of target GENES.Carcinoma, Large Cell: A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)Papilloma: A circumscribed benign epithelial tumor projecting from the surrounding surface; more precisely, a benign epithelial neoplasm consisting of villous or arborescent outgrowths of fibrovascular stroma covered by neoplastic cells. (Stedman, 25th ed)Hepatic Duct, Common: Predominantly extrahepatic bile duct which is formed by the junction of the right and left hepatic ducts, which are predominantly intrahepatic, and, in turn, joins the cystic duct to form the common bile duct.Prostatic Intraepithelial Neoplasia: A premalignant change arising in the prostatic epithelium, regarded as the most important and most likely precursor of prostatic adenocarcinoma. The neoplasia takes the form of an intra-acinar or ductal proliferation of secretory cells with unequivocal nuclear anaplasia, which corresponds to nuclear grade 2 and 3 invasive prostate cancer.Endoscopy: Procedures of applying ENDOSCOPES for disease diagnosis and treatment. Endoscopy involves passing an optical instrument through a small incision in the skin i.e., percutaneous; or through a natural orifice and along natural body pathways such as the digestive tract; and/or through an incision in the wall of a tubular structure or organ, i.e. transluminal, to examine or perform surgery on the interior parts of the body.Fibroadenoma: An adenoma containing fibrous tissue. It should be differentiated from ADENOFIBROMA which is a tumor composed of connective tissue (fibroma) containing glandular (adeno-) structures. (From Dorland, 27th ed)Mammary Neoplasms, Experimental: Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.Methylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.Fatal Outcome: Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Laryngeal Neoplasms: Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Uterine Cervical Neoplasms: Tumors or cancer of the UTERINE CERVIX.Pancreatitis, Acute Necrotizing: A severe form of acute INFLAMMATION of the PANCREAS characterized by one or more areas of NECROSIS in the pancreas with varying degree of involvement of the surrounding tissues or organ systems. Massive pancreatic necrosis may lead to DIABETES MELLITUS, and malabsorption.Mammary Neoplasms, Animal: Tumors or cancer of the MAMMARY GLAND in animals (MAMMARY GLANDS, ANIMAL).Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Mucin-1: Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.Digestive System Fistula: An abnormal passage communicating between any components of the digestive system, or between any part of the digestive system and surrounding organ(s).Neoplasm Transplantation: Experimental transplantation of neoplasms in laboratory animals for research purposes.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Adenocarcinoma, Follicular: An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)Mastectomy: Surgical procedure to remove one or both breasts.Ultrasonography, Mammary: Use of ultrasound for imaging the breast. The most frequent application is the diagnosis of neoplasms of the female breast.Tomography Scanners, X-Ray Computed: X-ray image-detecting devices that make a focused image of body structures lying in a predetermined plane from which more complex images are computed.Jaundice, Obstructive: Jaundice, the condition with yellowish staining of the skin and mucous membranes, that is due to impaired BILE flow in the BILIARY TRACT, such as INTRAHEPATIC CHOLESTASIS, or EXTRAHEPATIC CHOLESTASIS.Mammary Glands, Human: Glandular tissue in the BREAST of human that is under the influence of hormones such as ESTROGENS; PROGESTINS; and PROLACTIN. In WOMEN, after PARTURITION, the mammary glands secrete milk (MILK, HUMAN) for the nourishment of the young.Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Biopsy, Fine-Needle: Using fine needles (finer than 22-gauge) to remove tissue or fluid specimens from the living body for examination in the pathology laboratory and for disease diagnosis.Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.Cytodiagnosis: Diagnosis of the type and, when feasible, the cause of a pathologic process by means of microscopic study of cells in an exudate or other form of body fluid. (Stedman, 26th ed)Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Genes, Tumor Suppressor: Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.Predictive Value of Tests: In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.Magnetic Resonance Imaging: Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.Embryonal Carcinoma Stem Cells: The malignant stem cells of TERATOCARCINOMAS, which resemble pluripotent stem cells of the BLASTOCYST INNER CELL MASS. The EC cells can be grown in vitro, and experimentally induced to differentiate. They are used as a model system for studying early embryonic cell differentiation.Fibrocystic Breast Disease: A common and benign breast disease characterized by varying degree of fibrocystic changes in the breast tissue. There are three major patterns of morphological changes, including FIBROSIS, formation of CYSTS, and proliferation of glandular tissue (adenosis). The fibrocystic breast has a dense irregular, lumpy, bumpy consistency.Bile Ducts: The channels that collect and transport the bile secretion from the BILE CANALICULI, the smallest branch of the BILIARY TRACT in the LIVER, through the bile ductules, the bile ducts out the liver, and to the GALLBLADDER for storage.Cholangiography: An imaging test of the BILIARY TRACT in which a contrast dye (RADIOPAQUE MEDIA) is injected into the BILE DUCT and x-ray pictures are taken.Carcinoma, Papillary, Follicular: A thyroid neoplasm of mixed papillary and follicular arrangement. Its biological behavior and prognosis is the same as that of a papillary adenocarcinoma of the thyroid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1271)Endoscopes, Gastrointestinal: Instruments for the visual examination of the interior of the gastrointestinal tract.Gallbladder Neoplasms: Tumors or cancer of the gallbladder.Carcinoma, Non-Small-Cell Lung: A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.Biliary Tract Surgical Procedures: Any surgical procedure performed on the biliary tract.IndianaKaplan-Meier Estimate: A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)CA-19-9 Antigen: Sialylated Lewis blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors.Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.Adenocarcinoma, Clear Cell: An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.Cell Proliferation: All of the processes involved in increasing CELL NUMBER including CELL DIVISION.Cyclin-Dependent Kinase Inhibitor p16: A product of the p16 tumor suppressor gene (GENES, P16). It is also called INK4 or INK4A because it is the prototype member of the INK4 CYCLIN-DEPENDENT KINASE INHIBITORS. This protein is produced from the alpha mRNA transcript of the p16 gene. The other gene product, produced from the alternatively spliced beta transcript, is TUMOR SUPPRESSOR PROTEIN P14ARF. Both p16 gene products have tumor suppressor functions.Cholestasis, Extrahepatic: Impairment of bile flow in the large BILE DUCTS by mechanical obstruction or stricture due to benign or malignant processes.alpha-Fetoproteins: The first alpha-globulins to appear in mammalian sera during FETAL DEVELOPMENT and the dominant serum proteins in early embryonic life.Tongue Neoplasms: Tumors or cancer of the TONGUE.Apoptosis: One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.Pseudomyxoma Peritonei: A condition characterized by poorly-circumscribed gelatinous masses filled with malignant mucin-secreting cells. Forty-five percent of pseudomyxomas arise from the ovary, usually in a mucinous cystadenocarcinoma (CYSTADENOCARCINOMA, MUCINOUS), which has prognostic significance. Pseudomyxoma peritonei must be differentiated from mucinous spillage into the peritoneum by a benign mucocele of the appendix. (Segen, Dictionary of Modern Medicine, 1992)Dilatation, Pathologic: The condition of an anatomical structure's being dilated beyond normal dimensions.Cystadenocarcinoma, Serous: A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.Hepatectomy: Excision of all or part of the liver. (Dorland, 28th ed)Carcinoma, Lewis Lung: A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.Mammography: Radiographic examination of the breast.Calculi: An abnormal concretion occurring mostly in the urinary and biliary tracts, usually composed of mineral salts. Also called stones.Mammary Glands, Animal: MAMMARY GLANDS in the non-human MAMMALS.Tumor Suppressor Proteins: Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.Biopsy, Needle: Removal and examination of tissue obtained through a transdermal needle inserted into the specific region, organ, or tissue being analyzed.Bronchial Neoplasms: Tumors or cancer of the BRONCHI.Cell Division: The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.Microsatellite Repeats: A variety of simple repeat sequences that are distributed throughout the GENOME. They are characterized by a short repeat unit of 2-8 basepairs that is repeated up to 100 times. They are also known as short tandem repeats (STRs).Salivary Gland Neoplasms: Tumors or cancer of the SALIVARY GLANDS.Tissue Array Analysis: The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.DNA Mutational Analysis: Biochemical identification of mutational changes in a nucleotide sequence.Cholestasis: Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).Keratins: A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.Cisplatin: An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.Proto-Oncogene Proteins: Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.Lymph Nodes: They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.RNA, Neoplasm: RNA present in neoplastic tissue.DNA-Binding Proteins: Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.Paraffin Embedding: The infiltrating of tissue specimens with paraffin, as a supporting substance, to prepare for sectioning with a microtome.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Pancreatic Fistula: Abnormal passage communicating with the PANCREAS.Transplantation, Heterologous: Transplantation between animals of different species.

High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. (1/1031)

To determine the contribution of BRCA1 and BRCA2 mutations to the pathogenesis of male breast cancer in Hungary, the country with the highest male breast cancer mortality rates in continental Europe, a series of 18 male breast cancer patients and three patients with gynecomastia was analyzed for germ-line mutations in both BRCA1 and BRCA2. Although no germ-line BRCA1 mutation was observed, 6 of the 18 male breast cancer cases (33%) carried truncating mutations in the BRCA2 gene. Unexpectedly, none of them reported a family history for breast/ovarian cancer. Four of six truncating mutations were novel, and two mutations were recurrent. Four patients (22%) had a family history of breast/ovarian cancer in at least one first- or second-degree relative; however, no BRCA2 mutation was identified among them. No mutation was identified in either of the genes in the gynecomastias. These results provide evidence for a strong genetic component of male breast cancer in Hungary.  (+info)

VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. (2/1031)

Recently, monoclonal antibodies against the human vascular endothelial growth factor receptor VEGFR-3 were shown to provide a specific antigenic marker for lymphatic endothelium in various normal tissues. In this study we have investigated the expression of VEGFR-3 and its ligand VEGF-C in normal breast tissue and in breast tumors by immunohistochemistry. VEGFR-3 was weakly expressed in capillaries of normal breast tissue and in fibroadenomas. In intraductal breast carcinomas, VEGFR-3 was prominent in the "necklace" vessels adjacent to the basal lamina of the tumor-filled ducts. VEGF receptor 1 and 2 as well as blood vessel endothelial and basal lamina markers were colocalized with VEGFR-3 in many of these vessels. Antibodies against smooth muscle alpha-actin gave a weak staining of the necklace vessels, suggesting that they were incompletely covered by pericytes/smooth muscle cells. A highly elevated number of VEGFR-3 positive vessels was found in invasive breast cancer in comparison with histologically normal breast tissue (P < 0.0001, the Mann-Whitney test). VEGF-C was located in the cytoplasm of intraductal and invasive cancer cells. The results demonstrate that the expression of VEGFR-3 becomes up-regulated in the endothelium of angiogenic blood vessels in breast cancer. The results also suggest that VEGF-C secreted by the intraductal carcinoma cells acts predominantly as an angiogenic growth factor for blood vessels, although this paracrine signaling network between the cancer cells and the endothelium may also be involved in modifying the permeabilities of both blood and lymphatic vessels and metastasis formation.  (+info)

Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. (3/1031)

The generation of vascular stroma is essential for solid tumor growth and involves stimulatory and inhibiting factors as well as stromal components that regulate functions such as cellular adhesion, migration, and gene expression. In an effort to obtain a more integrated understanding of vascular stroma formation in breast carcinoma, we examined expression of the angiogenic factor vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF); the VPF/VEGF receptors flt-1 and KDR; thrombospondin-1, which has been reported to inhibit angiogenesis; and the stromal components collagen type I, total fibronectin, ED-A+ fibronectin, versican, and decorin by mRNA in situ hybridization on frozen sections of 113 blocks of breast tissue from 68 patients including 28 sections of breast tissue without malignancy, 18 with in situ carcinomas, 56 with invasive carcinomas, and 8 with metastatic carcinomas. A characteristic expression profile emerged that was remarkably similar in invasive carcinoma, carcinoma in situ, and metastatic carcinoma, with the following characteristics: strong tumor cell expression of VPF/VEGF; strong endothelial cell expression of VPF/VEGF receptors; strong expression of thrombospondin-1 by stromal cells and occasionally by tumor cells; and strong stromal cell expression of collagen type I, total fibronectin, ED-A+ fibronectin, versican, and decorin. The formation of vascular stroma preceded invasion, raising the possibility that tumor cells invade not into normal breast stroma but rather into a richly vascular stroma that they have induced. Similarly, tumor cells at sites of metastasis appear to induce the vascular stroma in which they grow. We conclude that a distinct pattern of mRNA expression characterizes the generation of vascular stroma in breast cancer and that the formation of vascular stroma may play a role not only in growth of the primary tumor but also in invasion and metastasis.  (+info)

An audit of breast cancer pathology reporting in Australia in 1995. (4/1031)

To measure the quality of pathology reporting of breast cancer and establish a baseline against which future changes can be measured, we audited item completeness in breast cancer reports in Australia in 1995 before the release of specific recommendations from the Australian Cancer Network. Tumour type and size were given in reports of invasive breast cancer for 93% of women, 70% had, in addition, grade and clearance of the margins while only 28% had all recommended information. The most complete items in reports were histological type of breast cancer (99.6% of cases), tumour size (94%, 95% confidence interval (CI) 92-95) and margins of excision (87%, 95% CI 85-89). Histological grade (84%, 95% CI 82-86 of cases) and presence or absence of ductal carcinoma in situ (DCIS) (79%, 95% CI 77-81) were less complete and vessel invasion (61%, 95% CI 58-63) and changes in non-neoplastic breast tissue adjacent to the breast cancer (68%, 95% CI 66-71) the least complete. Less than half the reports of DCIS reported on tumour size (49%, 95% CI 42-57), presence or absence of necrosis (41%, 95% CI 34-49) or nuclear grade (39%, 95% CI 31-46). Around 1500 reports were identified as issued by 147 laboratories and 392 pathologists; 69% of pathologists issued fewer than two reports a month in the audit. We concluded that infrequency of reporting may have contributed to incompleteness of reporting. In addition, we found significant variation across Australian states with some indication that reporting was consistently poor in one state. The audit highlighted areas for improvement for breast cancer reporting in Australia. Research evidence suggests that multifaceted strategies are needed to assist practitioners with implementing more uniform reporting standards.  (+info)

Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue. (5/1031)

Macrophages concentrate urokinase-type plasminogen activator (uPA) at the cell surface by expressing urokinase receptors (uPAR) in order to focus the pericellular space plasminogen-dependent proteolysis important in matrix remodeling and cell movement. This study examines the uPAR levels of tumor-associated macrophages (TAM) of invasive breast carcinomas, of TAMs from ductal carcinoma in situ (DCIS) and of macrophages derived from normal (non-tumor) breast tissue. TAMs from invasive breast carcinomas (n = 30), from DCIS (n = 12), and macrophages from normal breast tissue (n = 30) were cultured and immunocytochemically phenotyped by using a panel of antibodies. Urokinase receptor levels were determined by Western blot analysis and in cell-free supernatants by enzyme-linked immunosorbent assay. Urokinase receptor cell surface fluorescence intensity was determined by FACS and by confocal laser scan microscopy. Urokinase-receptor mRNA was detected by in situ hybridization. TAMs of invasive breast carcinomas and of DCIS possess significantly elevated uPAR levels compared with macrophages derived from normal breast tissue. CONCLUSIONS: activated macrophages with elevated uPAR levels belong to inflammatory areas in close vicinity of infiltrating and non-infiltrating (DCIS) tumor cells. Blood monocytes that possess elevated uPAR-levels may be selectively recruited from the bloodstream to inflammatory sites close to carcinoma cells, and/or breast cancer and precursor lesions may induce elevated uPAR-levels in TAMs by paracrine interactions.  (+info)

Primary tumour characteristics and axillary lymph node status in breast cancer. (6/1031)

This paper examines the correlation between axillary lymph node status and primary tumour characteristics in breast cancer and whether this can be used to select patients for axillary lymphadenectomy. The results are based on a retrospective analysis of 909 patients who underwent axillary dissection in our unit. Axillary lymph nodes containing metastases were found in 406 patients (44.7%), all with invasive carcinomas, but in none of the 37 carcinomas-in-situ. Nodal status was negative in all T1a tumours, but lymph node metastases were present in 16.3% and 35.7% of T1b and T1c tumours respectively. When histological grade was taken into account, positivity for grade I T1b and T1c tumours fell to 13.6% and 26.7% respectively. Lymph node metastases were found in 85% of patients with lymphovascular invasion in their tumours as compared to only 15.4% of those without and in 45.5% of oestrogen and progesterone receptor-positive tumours. When one or both hormone receptors were absent this figure was much higher. It appears that for T1a breast cancers axillary dissection is not necessary, whereas for T1b, T1c and grade I T2 tumours other histopathological parameters should be taken into consideration in deciding who should undergo axillary lymphadenectomy.  (+info)

Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. (7/1031)

Breast carcinoma is the most common malignant disease among women and the second most lethal one. In search for a better understanding of the role of cellular mediators in the progression of this disease, we investigated the potential involvement of the CC chemokine Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) in breast carcinoma progression. To this end, RANTES expression was determined in breast tumor cell lines and in sections of breast carcinomas, followed by analysis of the incidence and intensity of its expression in different stages of the disease. Our study reveals that high and physiologically relevant levels of RANTES are constitutively produced by T47D and MCF-7 breast tumor cell lines. Analysis of RANTES expression in sections of breast carcinomas demonstrates a high incidence of RANTES expression in epithelial tumor cells; the chemokine was expressed in 74% of the sections. RANTES expression was rarely detected in normal duct epithelial cells or in epithelial cells that constitute benign breast lumps, which were located in proximity to tumor cells. High incidence and intensity of RANTES expression were detected in sections of most of the patients with stage II and stage III of the disease (expression was detected in 83 and 83.3%, respectively), whereas RANTES was expressed at a lower incidence and intensity in sections of patients with stage I of breast carcinoma (55% of the cases). Most importantly, the expression of RANTES was minimally detected in sections of patients diagnosed with benign breast disorders and of women that underwent reduction mammoplasty (15.4% of the cases). These results indicate that the expression of RANTES is directly correlated with a more advanced stage of disease, suggesting that RANTES may be involved in breast cancer progression. Moreover, it is possible that in patients diagnosed with benign breast disorders, RANTES expression may be indicative of an ongoing, but as yet undetectable, malignant process.  (+info)

Prognosis in women with a carcinoma in situ of the breast: a population-based study in Sweden. (8/1031)

We studied the risk of invasive breast cancer and breast cancer death after a breast carcinoma in situ during a period when mammography screening became a nationwide practice and when breast conservation was introduced. In a study base including all 4661 women registered to the Swedish Cancer Registry for a first carcinoma in situ between 1960 and 1992, we selected a cohort of 3398 women diagnosed between 1980 and 1992. The recruitment period was chosen according to the reporting routines for the registry. The corrected survival was 97.4% after 10 years. The risk of invasive cancer was similar in the ipsilateral and contralateral breast. Women diagnosed between 1989 and 1992 ran a relative risk of 0.1 (95% confidence interval, 0.0-0.9) of dying of breast cancer, as compared with women diagnosed from 1980-1982. Residence in counties where mammography screening was available was associated with a relative risk of 0.2 (95% confidence interval, 0.0-2.1) for breast cancer death in the age groups screened. Screening mammography may have contributed to the improvement of prognosis over this time period. This study cannot distinguish between lead time effects and a "true" improvement in prognosis. The increased use of breast conservation was not associated with a worse prognosis in the group as a whole. The study indicates that at least 50% of invasive cancers occurring after treatment for in situ lesions may be new cancers.  (+info)

*Comedocarcinoma

It is usually a type of ductal carcinoma in situ. Comedo carcinomas are usually non-infiltrating and intraductal tumors. ... "Infiltrating ductal carcinoma breast with central necrosis closely mimicking ductal carcinoma in situ (comedo type): a case ... Comedo carcinoma entry in the public domain NCI Dictionary of Cancer Terms Images[dead link] comedocarcinoma [1] [2]. ... Bonnier P, Body G, Bessenay F, Charpin C, Fétissof F, Beedassy B, Lejeune C, Piana L. "Prognostic factors in ductal carcinoma ...

*List of MeSH codes (C04)

... carcinoma, pancreatic ductal MeSH C04.557.470.615.275 --- carcinoma, intraductal, noninfiltrating MeSH C04.557.470.615.275.625 ... carcinoma, hepatocellular MeSH C04.557.470.200.025.275 --- carcinoma, intraductal, noninfiltrating MeSH C04.557.470.200.025.275 ... carcinoma, ehrlich tumor MeSH C04.557.470.200.220 --- carcinoma, giant cell MeSH C04.557.470.200.240 --- carcinoma in situ MeSH ... carcinoma, krebs 2 MeSH C04.557.470.200.260 --- carcinoma, large cell MeSH C04.557.470.200.280 --- carcinoma, lewis lung MeSH ...

*International Classification of Diseases for Oncology

... noninfiltrating, NOS Intraductal adenocarcinoma, noninfiltrating, NOS Intraductal carcinoma, NOS Ductal carcinoma in situ, NOS ... Noninfiltrating intraductal papillary carcinoma Intraductal papillary adenocarcinoma, NOS Intraductal papillary carcinoma, NOS ... duct and lobular carcinoma in situ Intraductal and lobular carcinoma Infiltrating lobular carcinoma and ductal carcinoma in ... M8522/2 Intraductal carcinoma and lobular carcinoma in situ (C50._) M8522/3 Infiltrating duct and lobular carcinoma (C50._) ...
Patients diagnosed with ductal carcinoma in situ (DCIS) often opt for sentinel node surgery. But will that treatment prevent breast cancer progression?
FRIDAY, Oct. 25, 2019 (HealthDay News) - For each month of delay between diagnosis and surgery for ductal carcinoma in situ (DCIS), there is slightly worse survival and an increase in risk for invasive disease, according to a study published online Sept. 27 in the Annals of Surgical Oncology.. William H. Ward, M.D., from Naval Medical Center in Portsmouth, Virginia, and colleagues used the National Cancer Database to identify women with a clinical diagnosis of DCIS between 2004 and 2014. Differences in overall survival (OS) and presence of invasion were compared for five intervals between diagnosis and surgery (≤30, 31 to 60, 61 to 90, 91 to 120, and 121 to 365 days).. The researchers identified 140,615 clinical DCIS patients, of whom 123,947 had pathologic diagnosis of DCIS and 16,668 had invasive ductal carcinoma. Overall, five-year OS was 95.8 percent, and unadjusted median delay from diagnosis to surgery was 38 days. There was a 7.4 percent increased relative risk for death for each ...
Active surveillance could be a viable alternative to surgery and radiation for select patients with ductal carcinoma in situ, or DCIS, according to a mathematical model developed by researchers at Duke University.
Women diagnosed with DCIS have a very good prognosis. Ten years after DCIS diagnosis, 98% to 99% of women will be alive. Based on this good prognosis, DCIS usually is treated by lumpectomy followed by radiation therapy. If the DCIS is large, a mastectomy may be recommended. Removing the opposite breast usually isnt recommended; chemotherapy usually isnt recommended either. Hormonal therapy may be recommended if the DCIS is hormone-receptor-positive.. DCIS is NOT invasive cancer. DCIS stays inside the breast milk duct. DCIS can be large or small, but it does NOT spread outside the milk duct into the surrounding normal breast tissue or into the lymph nodes or other organs. Still, if youve been diagnosed with DCIS, youre at higher risk of developing invasive breast cancer in that breast than someone who hasnt had DCIS. DCIS also is referred to as stage 0 breast cancer.. After a DCIS diagnosis in one breast, the average risk of developing either DCIS or invasive breast cancer in the OPPOSITE ...
This multicentre retrospective study is characterised by a long period of accrual (median follow-up: 136 months,; range: 16-292 months), which offers the advantage of providing interesting information about the trend of the disease. A certain number of patients (12 patients) enrolled in the first years have died during this long period of observation; other patients (47 patients) didnt return for the planned examination to the Centre of Radiotherapy where they had been treated, and were lost to follow-up. In addition only approximately 20% of patients were treated in the first period (from 1985 to 1990) and the number of cases increased progressively during the following years (Figure 1). Most of the cases belong to the two decades covered by the screening activity. Nevertheless, a large number of cases were also found in the younger age group, between 41 and 50. Increased debate and publicity about breast cancer screening after the introduction of screening programmes could have determined an ...
The widespread adoption of screening mammography has led to an increase in the diagnosis of ductal carcinoma in situ (DCIS) of the breast. While it is estimated that 55,000 women in the US will be diagnosed with DCIS in 2013, only a small fraction of these women (~15%) will subsequently develop invasive breast cancer. However, most women with DCIS are treated as if they will develop invasive cancer. Almost a third of these women opt for a full mastectomy. In a majority of remaining women, the DCIS lesion is surgically excised with lumpectomy and, in over half of these women, additional radiation or tamoxifen treatment is provided. Thus, many women are receiving unnecessary adjuvant therapy to prevent invasive cancers that will not occur. Additionally, ~ 15% of women are not receiving adequate intervention because they will subsequently develop a subsequent invasive tumor even after receiving lumpectomy and adjuvant therapy. Identifying molecular markers that can accurately predict subsequent ...
Intraductal carcinoma of the prostate (IDCP) has been described as a lesion associated with poor prognostic features in prostate cancer. Its recognition and reporting in prostate specimens, particularly in needle biopsies, is critical as it carries significant implications for patient management. Recent histological definitions have been proposed to assist in the recognition of IDCP and to help distinguish it from lesions with similar appearance, but different clinical behaviour. In this review, a historical overview of the description of IDCP will be presented followed by a summary of the current histological diagnostic criteria and the recommendations for management and reporting of IDCP. ...
TY - JOUR. T1 - A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease. AU - Jakub, James W. AU - Murphy, Brittany L.. AU - Gonzalez, Alexandra B.. AU - Conners, Amy L.. AU - Henrichsen, Tara L.. AU - Maimone, Santo IV. AU - Keeney, Michael G.. AU - McLaughlin, Sarah A.. AU - Pockaj, Barbara A. AU - Chen, Beiyun. AU - Musonza, Tashinga. AU - Harmsen, William S.. AU - Boughey, Judy C. AU - Hieken, Tina J. AU - Habermann, Elizabeth B. AU - Shah, Harsh N.. AU - Degnim, Amy C. PY - 2017/8/1. Y1 - 2017/8/1. N2 - Background: Approximately 8-56% of patients with a core needle biopsy (CNB) diagnosis of ductal carcinoma in situ (DCIS) will be upstaged to invasive disease at the time of excision. Patients with invasive disease are recommended to undergo axillary nodal staging, most often requiring a second operation. We developed and validated a nomogram to preoperatively predict percentage of risk for upstaging to invasive cancer. Methods: We reviewed 834 cases of DCIS ...
HCC1937BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as HCC1937 (a primary breast ductal carcinoma cell line, ATCC CRL-2336).
A 33-year-old woman with a 2.7 cm high grade, comedo type DCIS, which was accurately assessed by both MRI and mammography.A. Spot-magnification mediolateral obl
Review of DCIS by a pathologist can identify prognostic features. Pathologists look at the following four distinct histologic features: Tumor size Necrosis presence Nuclear grade Width of surgical... more
New research from Amsterdam shows that women over the age of 50 who have been diagnosed with ductal carcinoma in situ have a higher chance of being alive ten years after their diagnosis than women in the general population, according to Science Daily. Ductal carcinoma in situ is considered a disease separate from breast cancer because it is at stage 0 and does not spread around the body. However, ductal carcinoma in situ can progress into full-blown breast cancer, which is why it is still treated with surgery or surgery in combination with radiation therapy.. The researcher Dr. Lotte Elshof presented findings at the European Cancer Congress 2017. Women who have been diagnosed with ductal carcinoma in situ should feel better about their future because of these findings, which show their longevity will not be impacted by this condition.. Dr. Jelle Wesseling and her team at the Netherlands Cancer Institute followed approximately 10,000 Dutch women with ductal carcinoma in situ between the years ...
approximately three-quarters of breast cancers Invasive ductal carcinoma - 55% of breast cancers Ductal carcinoma in situ - 13% Invasive lobular carcinoma - 5% The overall 5-year survival rate for both ... Ductal carcinoma in situ, on the other hand, is in itself harmless, although if untreated approximately 60% of these low grade DCIS lesions will become invasive over the course of 40 years in follow-up ...
Widespread screening mammography programmes mean that ductal carcinoma in situ (DCIS), a pre-invasive breast lesion, is now more frequently diagnosed. However, not all diagnosed DCIS lesions progress to invasive breast cancer, which presents a dilemma for clinicians. As such, there is much interest in studying DCIS in the laboratory, in order to help understand more about its biology and determine the characteristics of those that progress to invasion. Greater knowledge would lead to targeted and better DCIS treatment. Here, we outline some of the models available to study DCIS, with a particular focus on animal-free systems.. ...
RESULTS: 42 of the 99 lesions (42.4%) were invasive carcinomas, 57 (57.6%) were pure ductal carcinoma in situ (DCIS). 6 out of 99 (6.1%) lesions were triple negative, and 29 (29.3%) were HER2/neu positive. Successful first excision rate was 76/99 lesions (76.8%). Breast conservation was achieved in 73.7% (73/99). 10 women showed local recurrences without negatively impacting survival. The recurrences included round/punctate, amorphous, fine pleomorphic, and fine linear or fine-linear branching descriptors. The breast cancer-specific long-term survival rate was 91/94 (96.8%) for a mean follow-up of 81.4 months. The 3 patients who died due to breast carcinoma showed fine pleomorphic calcifications, and had nodal-positive invasive carcinoma at diagnosis ...
The micrometastasis was discovered because your surgeon performed an axillary lymph node dissection. A surgeon typically performs a lymph node dissection for ductal carcinoma in situ (DCIS) when there is extensive DCIS (like you had) or when a patient has a high-grade DCIS. When DCIS is high-grade, there are many dead cells in the duct, and the cells that are alive are very aberrant. In this situation there is a higher chance that microinvasion-a spot where the DCIS has crossed the line to invasion-has occurred.. It can be tricky to diagnose micrometastases in the sentinel node. Most likely your micrometastasis is due to cells that were displaced during surgery as opposed to an actual spread of cancer cells from the DCIS, especially if there was no invasion outside the duct. However, the only way to know this for sure is to have an expert in breast pathology determine if it is truly micrometastasis or if it is a displaced cell. This is why it is very important that you get a second opinion from ...
In conclusion, Dr. Lori Pierce, Vice Provost for Academic and Faculty Affairs and Professor of Radiation Oncology at the University of Michigan, says "this article has summarized nicely the major challenges facing breast cancer patients and their physicians in the management of ductal carcinoma in situ (DCIS). DCIS is not an invasive disease but can progress to invasive breast cancer, and potentially impact survival, in a significant number of women if not adequately treated when diagnosed. And we know that for those patients treated with lumpectomy, radiation to follow will reduce the chance of DCIS returning and/or invasive disease developing by at least 50%. We also know, however, that in some patients, the likelihood that DCIS will progress to invasive disease is very low even in the absence of treatment. Unfortunately, we have not found a reproducible way to predict those who need to be treated and those who dont but many researchers are working on this very question. For now, clinicians ...
Mai, K. T., Perkins, D. G. and Mirsky, D. (2003), Location and Extent of Positive Resection Margins and Ductal Carcinoma in Situ in Lumpectomy Specimens of Ductal Breast Carcinoma Examined with a Microscopic Three-Dimensional View. The Breast Journal, 9: 33-38. doi: 10.1046/j.1524-4741.2003.09108.x ...
A small, early study suggests that a shorter, higher-dose radiation schedule after lumpectomy to remove DCIS (ductal carcinoma in situ) may reduce the risk of the cancer coming back (recurrence) just as much as a standard radiation treatment schedule.. The study was published in the June 2012 issue of the International Journal of Radiation Oncology*Biology*Physics. Read the abstract of "Five Year Outcome of 145 Patients With Ductal Carcinoma In Situ (DCIS) After Accelerated Breast Radiotherapy.". DCIS is the most common form of non-invasive breast cancer. DCIS is called "non-invasive" because it hasnt spread beyond the milk duct into any normal surrounding breast tissue. DCIS isnt life-threatening, but having DCIS can increase the risk of developing an invasive breast cancer later on. DCIS usually is treated with surgery to remove the cancer, lumpectomy in most cases. After surgery, many women have radiation therapy.. Radiation therapy after breast cancer surgery is most commonly given as 25 ...
Although a precursor to breast cancer, DCIS can progress to become invasive disease and thus is normally treated with surgery, sometimes in combination with radiotherapy.. The team of researcher behind this new work, based at the Netherlands Cancer Institute (The Netherlands), hope that their results may provide reassurance to those women diagnosed with DCIS. Overall the findings indicate that although these individuals have an increased risk of dying from breast cancer, they actually have a slightly lower risk of dying from any cause.. Under the instruction of Jelle Wesseling (Netherlands Cancer Institute), the team analyzed data from 10,000 Dutch women diagnosed with DCIS from 1989 to 2004. They tracked the data from these patients over an average 10-year period and compared mortality rates with the expected mortality of the general population.. In terms of breast cancer mortality risk, the study demonstrated that DCIS patients had a 2.5% risk of dying from breast cancer 10 years after ...
There are a few things about ductal carcinoma in situ (DCIS) on which everyone agrees: Incidence increased dramatically with the advent of mammography screening, not all cases detected will go on to cause symptoms in the patients lifetime, and theres no proven way to tell which cases will progress.. But agreement often ends when it comes to clinical management. Should all cases be treated with surgery and radiation in the absence of proven markers to show which cases will progress? Or is watch-and-wait an option? Can existing tools be used to guide the decision?. Experts put their views on the line in a debate at the 66th Annual Cancer Symposium of the Society of Surgical Oncology, held March 6-9 in Washington, DC.. Battle Lines Drawn. "All DCIS patients benefit from standard therapy," declared Thomas B. Julian, MD, a Professor of Surgery at Drexel and Temple Universities in Philadelphia, who took the pro-treatment position in the debate-format session.. DCIS is a heterogeneous disease that is ...
Mucinous breast carcinoma with a lobular neoplasia component : a subset with aberrant expression of cell adhesion and polarity molecules and lack of neuroendocrine differentiation(審査報告)Mucinous breast carcinoma with a lobular neoplasia component : a subset with aberrant expression of cell adhesion and polarity molecules and lack of neuroendocrine differentiation(審査報告) ...
Another interesting finding in our study is that women greater than 55 years of age with atypia had increased ER expression compared with younger women with atypia. This differs from the previous report by Shoker and colleagues (7) who found that ER expression was high in atypical ductal hyperplasia, ductal carcinoma in situ and lobular neoplasia regardless of age. The number of samples in that study was somewhat small; 23 cases of atypical hyperplasia, 43 cases of ductal carcinoma in situ, and 32 cases of lobular neoplasia. The authors suggested that in atypia and carcinoma in situ the regulation of ER expression may escape the normal age-related regulatory mechanisms. ER expression and relationship to age has also been studied in hyperplastic enlarged lobular units, a common alteration of the normal TDLU and potential precursor of breast cancer. Lee and colleagues (21) have shown that ER expression in hyperplastic enlarged lobular units is increased in postmenopausal woman compared with ...
Hollie Quinn suffered from the typical health complaints of an adult female; these included heartburn and acid reflux, along with painful cysts, vertigo and migraines.. Hollie says that she ate the typically American diet which was low in vegetables, high in sugar, and drank soda daily. She never questioned the health directives given to her by her doctors, and was never told that there might be a connection between her health issues and the diet that she was eating.. In 2002, when Hollie was just 27 years old and in her 38th week of pregnancy, she was diagnosed with an infiltrating ductal carcinoma. This is the most common type of breast cancer which affects some 80% of patients, and as its name suggests, the cancer had broken through the milk duct and was invading the surrounding tissues of the breast. Over time, invasive ductal carcinomas can spread to the lymph nodes and to other areas of the body. Hollies main tumor was 2.3 cm, with a second tumor measuring 0.6 cm. The larger tumor was a ...
AIM: The traditional architecture based classification system of ductal carcinoma in situ (DCIS) has been criticised on the grounds that individual lesions often show more than one pattern resulting in a large mixed category. New DCIS classification systems have emphasised the importance of cytological grade, which is reputed to be more uniformly expressed throughout a lesion. This study investigates the hypothesis that cytological heterogeneity is less common than architectural heterogeneity within DCIS lesions. METHODS: 121 cases of DCIS were graded as poorly, intermediately, or well differentiated according to a recently developed classification system that employs cytonuclear morphology as the major diagnostic criterion. Cases were categorised as pure when only one grade was present and as mixed if more than one grade was observed. Architecturally the cases were classified as solid, cribriform, micropapillary, or papillary and were described as pure if only one architectural pattern was ...
Here, we show that SOX11, an embryonic mammary marker that is normally silent in postnatal breast cells, is expressed in many oestrogen receptor-negative preinvasive ductal carcinoma in situ (DCIS) lesions. Mature mammary epithelial cells engineered to express SOX11 showed alterations in progenitor cell populations, including an expanded basal-like population with increased aldehyde dehydrogenase (ALDH) activity, and increased mammosphere-forming capacity. DCIS.com cells engineered to express SOX11 showed increased ALDH activity, which is a feature of cancer stem cells. The CD44+/CD24-/ALDH+ cell population was increased in DCIS.com cells that expressed SOX11. Upregulating SOX11 expression in DCIS.com cells led to increased invasive growth both in vitro and when they were injected intraductally in a mouse model of DCIS that recapitulates human disease. Invasive lesions formed sooner and tumour growth was augmented in vivo, suggesting that SOX11 contributes to the progression of DCIS to invasive ...
The distribution of ductal carcinoma in situ DCIS grade in 4232 women and its impact on overdiagnosis in breast cancer screening. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Rita - Patient: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Currently in active treatment (initial surgery, receiving chemo rounds/radiation), Diagnosed: almost 7 years ago, Female, Age: 50, Stage 0
copland16 - Survivor: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Finished active treatment less than 5 years ago, Diagnosed: over 9 years ago, Female, Age: 48, Stage II, HER2 Positive: No, ER Positive: Yes, PR Positive: Yes
penny364 - Survivor: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Finished active treatment less than 5 years ago, Diagnosed: about 5 years ago, Female, Age: 71, Stage 0, HER2 Positive: No, ER Positive: Yes, PR Positive: Yes
fortysomething - Survivor: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Finished active treatment less than 5 years ago, Diagnosed: over 11 years ago, Female, Age: 50
Introduction Ductal carcinoma in situ (DCIS) is a common pre-invasive malignancy of the breast, representing approximately 20% of all breast cancer diagnoses...
RATIONALE: Diagnostic procedures, such as MRI, may help find ductal carcinoma in situ and find out how far the disease has spread.PURPOSE: This
Zamecnik, M. Atypical cystic lobules: an advancing edge of low-grade ductal carcinoma in situ?. Virchows Archiv 437, 469 (2000). https://doi.org/10.1007/s004280000253. Download ...
All structured data from the main and property namespace is available under the Creative Commons CC0 License; text in the other namespaces is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. ...
The differential expression of PDCD4 (in cancer cells) and miR-21 (in stromal cells) cannot alone form the basis for arguing that miR-21 is dynamically targeting PDCD4. Interestingly, we identified miR-21 in a subset of normal mammary glands and in some high-grade breast tumors - including pre-invasive DCIS lesions (ductal carcinoma in situ, considered the earliest form of breast cancer). We observed that miR-21 can indeed be expressed in normal epithelial and in cancer cells (Nielsen et al., 2014, Frontiers in Oncology ...
WILMINGTON, Del-AstraZen-eca announced in a news release that the FDA has approved Nolvadex (tamoxifen) to reduce the risk of invasive breast cancer in women with ductal carcinoma in situ (DCIS) following breast surgery and radiation. Nolvadex is the first medication to be approved for DCIS, which accounts for nearly 20% of all newly diagnosed breast cancers, the company said. 1
Most women usually opt for a lumpectomy with or without additional treatments such as for example radiation, hormonal therapy or chemotherapy. However, since the most DCIS lesions arent associated with formation of subsequent invasive tumors, chances are that many women identified as having DCIS are becoming over treated. Approximately 12-15 % of ladies diagnosed with DCIS create a subsequent invasive tumor within a decade after undergoing medical lumpectomy. Related StoriesCornell biomedical engineers develop very natural killer cells to destroy cancer cells in lymph nodesViralytics enters into scientific trial collaboration agreement with MSDMeat-rich diet may increase kidney tumor riskAs noted in the study, it is well known that normal cellular responses to stress are essential barriers to cancer development and therefore provide researchers with molecular candidates to greatly help identify lesions that wont progress to a malignancy.It is necessary that the very best use is made from ...
Investigating multiple samples (n={}25) from four patients we found an average of 5.6 ± 0.9 (mean ± SEM) chromosomal imbalances already present in DH. In the twelve DCIS lesions an average of 10.8 (±0.9) aberrations was identified with 14.8 (±0.8) aberrations in the four adjacent IDC lesions. The increasing number of chromosomal changes in parallel with the histopathological sequence corroborate the hypothesis, that the carcinomas may have developed through a sequential progression from normal to proliferative epithelium and eventually into carcinoma. However, heterogeneous results were identified in the multiple samples per entity from the same patient, demonstrated mainly in the DCIS samples in the chromosomal regions 6p, 9p, 11q, 16p and 17q, in the DH samples by 3p, 16p and 17q. This heterogeneous findings were most pronounced within the DH and was less in the DCIS and IDC samples. The only aberration consistently found in all samples - even in all DH samples - was amplification of the ...
Radiotherapy treatment (RT) after surgery for ductal carcinoma in situ (DCIS) has a major protective effect against recurrence more than 15 years later, according to the results of an international trial presented March 22 at the 8th European Breast Cancer Conference (EBCC-8).
Hi, My doctory just called me with the results of my biopsy. The report says APPROACHING the lowest grade of dcis. I asked my doctor if this means benign or malignant, and he said inbetween. I asked...
Ductal carcinoma in situ is the fourth most common cancer diagnosis in women. Some say its not "really" cancer. But you wouldnt know that based on how it is treated.. by Sue Rochman ...
Looking for JET-LUBE Anti Seize,Nonmetallic,Nuclear Grade? Graingers got your back. Clearance Price:$38.48. Easy ordering & convenient delivery. Log-in or register for your pricing.
Abstract Ductal carcinoma in situ (DCIS) is an intraductal neoplastic proliferation of epithelial cells that is separated from the breast stroma by an intact layer of basement membrane and myoepithelial cells. DCIS is a non-obligate precursor of invasive breast cancer, and up to 40% of these lesions progress to invasive disease if untreated. Currently, it is not possible to predict accurately which DCIS would be more likely to progress to invasive breast cancer as neither the significant drivers of the invasive transition have been identified, nor has the clinical utility of tests predicting the likelihood of progression been demonstrated. Although molecular studies have shown that qualitatively, synchronous DCIS and invasive breast cancers are remarkably similar, there is burgeoning evidence to demonstrate that intra-tumor genetic heterogeneity is observed in a subset of DCIS, and that the process of progression to invasive disease may constitute an evolutionary bottleneck, resulting in the ...
Atypical ductal hyperplasia is a condition that can occur in the lining of the milk ducts in the breast. ADH is not a form of breast cancer.
Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive cancerous lesion of the breast. DCIS is classified as Stage 0. It rarely produces symptoms or a breast lump one can feel, and is usually detected through screening mammography. In DCIS, abnormal cells are found in the lining of one or more milk ducts in the breast. In situ means "in place" and refers to the fact that the abnormal cells have not moved out of the mammary duct and into any of the surrounding tissues in the breast ("pre-cancerous" refers to the fact that it has not yet become an invasive cancer). In some cases, DCIS may become invasive and spread to other tissues, but there is no way of determining which lesions will remain stable without treatment, and which will go on to become invasive. DCIS encompasses a wide spectrum of diseases ranging from low-grade lesions that are not life-threatening to high-grade (i.e. potentially highly aggressive) lesions. DCIS has been classified ...
Invasive ductal carcinoma is the most commonly diagnosed breast cancer and has a tendency to metastasize via lymphatics. This lesion, which accounts for 75% of breast cancers, has no specific histolog... more
OBJECTIVE: To determine the rates of diagnostic underestimation at stereotactic percutaneous core needle biopsies (CNB) and vacuum-assisted biopsies (VABB) of nonpalpable breast lesions, with histopathological results of atypical ductal hyperplasia (ADH) or ductal carcinoma in situ (DCIS) subsequently submitted to surgical excision. As a secondary objective, the frequency of ADH and DCIS was determined for the cases submitted to biopsy. MATERIALS AND METHODS: Retrospective review of 40 cases with diagnosis of ADH or DCIS on the basis of biopsies performed between February 2011 and July 2013, subsequently submitted to surgery, whose histopathological reports were available in the internal information system ...
Most DCIS arises in the larger ducts and LCIS arises within the lobules of the breast. However, the ducts and lobules are connected which means that DCIS may travel into the lobules and LCIS may travel up the ducts. For this reason, pathologists rely on the type of cells and pattern of growth to determine the diagnosis of DCIS vs. LCIS. Only a pathologist can make this distinction. In some cases, both DCIS and LCIS are present in the same biopsy.. DCIS and LCIS both increase a patients relative risk for developing invasive breast cancer and that risk applies to both breasts. However, DCIS is also thought to be a "precursor" to invasive carcinoma based upon numerous research studies. This is why your surgeon tries to remove all areas of DCIS from your breast and why many patients subsequently receive radiation therapy to that breast.. LCIS, on the other hand, has not traditionally been considered to be a "precursor" to invasive carcinoma, therefore complete removal of LCIS and radiation therapy ...
Ductal carcinoma in situ (DCIS) is a pre-invasive, early form of breast cancer. Find more about how DCIS is diagnosed and treated at Breast Cancer Now.
Symptoms, diagnosis, treatment and prognosis for invasive ductal carcinoma-from the Johns Hopkins Breast Center in Baltimore, MD. Also get info for medullary, mucinous, papillary and tubular ductal carcinomas.
REDWOOD CITY, Calif. and PHILADELPHIA, May 2, 2013 /PRNewswire/ - Genomic Health, Inc. (Nasdaq: GHDX) and the ECOG-ACRIN Cancer Research Group announced today that the Journal of the National Cancer Institute (JNCI) published positive results from their clinical validation study of the Oncotype DX® DCIS Score in patients with ductal carcinoma in situ (DCIS), an early or pre-invasive form of breast cancer. The prospective study, designed and conducted jointly by Genomic Health and ECOG-ACRIN, established that the Oncotype DX DCIS Score goes beyond traditional clinical and pathologic measures to predict the 10-year risk of local recurrence, defined as recurrence of DCIS or invasive breast cancer in the same breast, a finding that will help to guide radiation treatment decision-making for women with DCIS who are treated by local excision. The study was published online today and is scheduled to appear in Volume 105, Issue 10 of the JNCI print edition.. To view the multimedia assets associated with ...
Ductal carcinoma in situ (DCIS) occurs when some of the cells that line a group of milk ducts within your breast have started to become cancer cells.
Mammography screening is deemed cost-effective for women aged 50-70. Yet the utilities informing breast screening policy are limited in their ability to adequately capture the benefits and risks. The evaluation of many cancer screening programmes present results in terms of cost per QALY but fail to include any disutility for the patients who have been over-diagnosed and may receive unnecessary treatment. This thesis presents an overview of the challenges associated with valuing breast cancer states, using the results of an empirical study deriving utilities from 172 women in Melbourne, Australia as an example of potential methods to capture the disutility of overtreatment. Ductal carcinoma in situ was used as a proxy to quantify the benefits and harms associated with the sequelae of screening. Utilities derived from 172 women for health states explicitly describing overdiagnosis were lower than those from the literature, where it is unlikely that women were informed that their treatment may ...
This represents fantastically good news for all women (and not just those who may have been needlessly treated for breast cancer). For one thing, it means that what we think of as the most deadly of lady killers is not anywhere near as epidemic as we think. We have imagined ductal carcinoma in situ (DCIS), in the main, to be a herald of breast cancer, much as we imagine that abnormal smear tests are an early-warning sign of cervical cancer. But DCIS may well turn out to be a harmless aberration that, like abnormal smear tests, in the majority of cases doesnt progress to cancer. Indeed, women with DCIS might never become aware of it if medicine didnt insist on a blunderbuss means of screening for cancer. Insisting on surgery for DCIS is as barbaric as performing a hysterectomy on a woman with a dodgy Pap smear, a common practice a generation ago ...
I have in me the DNA of both my mother and my father. For a year now I have walked the line where doctors have essentially said "im on the edge" of cells turning to cancer. After my first lumpectomy it was simply one site of abnormal cells (atypical ductal hyperplasia). My second lumpectomy 6 months later after another mass grew in my left breast was now two sites with atypical cells, but this time, the pathologists said it was borderline DCIS (ductal carcinoma in situ). At the same I was also struggling with stomach pain, fatigue and weight loss. I lost 34 pounds in a year without trying. After numerous procedures and tests, my GI diagnosed me with pancreatic insufficiency in March of this year. What he does know is that my pancreas no longer produces lipase, an enzyme that digests fats. What he is unable to tell me is why. "Its good we know what is causing your weight loss and that the pancreatic enzymes help. Its not so good we dont know why," my doctor says. He wants to monitor me ...
Overdiagnosis and overtreatment resulting from mammographic screening have been estimated to be as high as 1 in 4 patients diagnosed with breast cancer although the absence of standard definitions for measuring overdiagnosis has led to much uncertainty around this estimate. The national health care expenditure resulting from false positive mammograms and breast cancer overdiagnosis has been estimated to approach $4 billion annually. There is general consensus that much of this burden derives from the treatment of DCIS; for those estimated 40,000 women per year whose DCIS may never have progressed even without treatment, medical intervention can only harm. In those women who undergo surgical management of DCIS, there is risk of developing persistent pain at the surgical site, with estimates ranging from 25-68%. Importantly, persistent pain after lumpectomy may be as prevalent as that after total mastectomy. Persistent postsurgical pain is rated by patients as the most troubling symptom, leading ...
TY - JOUR. T1 - Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features. T2 - a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. AU - Rakovitch, E.. AU - Gray, R.. AU - Baehner, F. L.. AU - Sutradhar, R.. AU - Crager, M.. AU - Gu, S.. AU - Nofech-Mozes, S.. AU - Badve, S. S.. AU - Hanna, W.. AU - Hughes, L. L.. AU - Wood, W. C.. AU - Davidson, N. E.. AU - Paszat, L.. AU - Shak, S.. AU - Sparano, J. A.. AU - Solin, L. J.. PY - 2018/6/1. Y1 - 2018/6/1. N2 - Purpose: Better tools are needed to estimate local recurrence (LR) risk after breast-conserving surgery (BCS) for DCIS. The DCIS score (DS) was validated as a predictor of LR in E5194 and Ontario DCIS cohort (ODC) after BCS. We combined data from E5194 and ODC adjusting for clinicopathological factors to provide refined estimates of the 10-year risk of LR after treatment by BCS alone. Methods: Data from E5194 and ODC were combined. Patients with positive margins or multifocality ...
MarcieB - Patient: Breast Cancer > Invasive (Infiltrating) Ductal Carcinoma Patient Info: Currently in active treatment (initial surgery, receiving chemo rounds/radiation), Diagnosed: over 1 year ago, Female, Age: 72, Stage II, HER2 Positive: Yes, ER Positive: Yes, PR Positive: Yes
Dr. Ansanellis laser surgery serves as a tremendous benefit to a Ductal Carcinoma In Situ patient as it greatly reduces the chance of cancer cell spread.
After having a lumpectomy, chemo and radiation my wife is 2 1/2 years out from treatment and has a recurrence. She is scheduled for a mastectomy. What type of follow up treatment is availible? Her 1...
Cornfield D B, Schwartz G F, Shen R, McDade T, Kovatich A. (1996, May). Histologic and Immunohistochemical Features of Ductal Carcinoma In Situ of the Breast Recurring After Wide Excision Alone. Presentation presented at: 32nd annual Meeting of the American Soc Clinical Oncol, Philadelphia, PA.. ...
classification and prognostic scoring along with quantification of immune cells/mm [2] was performed. Data were entered and analyzed using SPSS version 16. Correlation of immune cell densities with various tumour sub-types was investigated using paired t-test and ANOVA. A p-value of ...
This project investigated whether the release of national clinical practice recommendations for Ductal Carcinoma In Situ (DCIS) influenced clinical practice.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
荊 雪楓 , 覚道 健一 , 村上 真紀 , 中村 靖司 , 中村 美砂 , 横井 豊治 , 尾浦 正二 , 桜井 武男 ホルモンと臨牀 46, 157-166, 1998-09-30 医中誌Web 参考文献23件 ...
You have cancer!" Despite all treatment options, this diagnosis has not lost any of its terror. Many patients who are confronted with this message from their doctor feel existentially threatened, or at least feel thrown off track. This is only too understandable when they imperatively want to get rid of the malignant tumour in their body - even though one could just wait and see.. The latter approach is an alternative for example in cases of ductal carcinoma in situ (DCIS). One in five women with newly discovered breast cancer actually has this diagnosis. As a general rule, the tumour is surgically removed or irradiated. However, DCIS is strictly speaking not a real cancer, but a precursor. And the risk that a true cancer develops from it is specified as being about 20 percent over a period of up to 40 years with low malignancy tumour cells. Instead of a therapy, regular check-ups therefore also enter the realm of possibilities.. ...
This is a pilot study designed to investigate new techniques to guide the appropriate diagnosis and treatment of Ductal Carcinoma In-situ (DCIS). The m
I have been delving into the vast amount of knowledge and information online concerning the condition of my breasts, being fine calcification. The concern is DCIS (Ductal Carcinoma In-Situ) a condition that is considered stage 0/or pre-cancer, which can become invasive cancer at any given time, they just dont know. Uh-oh, I am a typical addict, I tend to overdo/over think things, fall into extreme thought patterns, assume the worst,…
Gene expression profiling has taught us a great deal about the progression of fully-developed invasive breast cancer, and our study used this approach as a starting point to learn more about the progression of DCIS to invasive breast cancer. We are aware of at least 9 previous studies comparing expression between DCIS and invasive breast cancer, publishing results that can be compared with ours (8-16, 30). Collectively, these studies included 130 cases of DCIS and 126 of invasive breast cancer, which pales in comparison to previous expression profiling studies of invasive breast cancer alone involving thousands of cases. Our study increases the number of samples comparing DCIS to invasive breast cancer by about 50%, which is a helpful contribution given the relatively small numbers of cases overall addressing this important question.. A proportion of samples from this (17%) and the previous (37%) studies were paired DCIS and invasive breast cancer from the same breasts, which may not be the ...
Ductal carcinoma in situ is a noninvasive precancer condition. The treatment resembles the treatment of invasive breast cancer. The aim of this exploratory study was to gain knowledge on the level of postoperative pain, sensory disturbances, and distress among a small group of Danish women with ductal carcinoma in situ who had sentinel lymph node biopsy in order to plan a population study. A subgroup of patients with ductal carcinoma in situ (n = 20) was compared to patients with invasive breast cancer (n = 455) at time of diagnosis and after 12 months. Six patients were interviewed on the impact of the diagnosis and life after treatment. We found no significant difference in reported sensory disturbances or pain after 12 months between the groups. More than one-third (39%) of ductal carcinoma in situ patients reported moderate to severe distress (≥ 7 on the Distress Thermometer) at time of diagnosis decreasing to 10% after 12 months. Similarly 36% of breast cancer patients reported distress ...
ConferenceSeries organizes Invasive Ductal Carcinoma national symposiums, conferences across the globe in association with popular Invasive Ductal Carcinoma associations and companies. OMICS group planned its conferences, and events in america, europe, middle east and asia pacific. locations which are popular with international conferences, symposiums and events are china, canada, dubai, uae, france, spain, india, australia, italy, germany, singapore, malaysia, brazil, south korea, san francisco, las vegas, san antonio, omaha, orlando, raleigh, santa clara, chicago, philadelphia, baltimore, united kingdom, valencia, dubai, beijing, hyderabad, bengaluru and mumbai
Tubular carcinoma (TC) is an uncommon special type of breast cancer characterized by an indolent clinical course. Although described as part of a spectrum of related lesions named low-grade breast neoplasia family due to immunophenotypical and genetic similarities, TCs, low-grade invasive ductal carcinomas of no special type (IDC-NSTs), and classic invasive lobular carcinomas (ILCs) significantly differ in terms of histological features and clinical outcome. The aim of this study was to investigate whether pure TCs constitute an entity distinct from low-grade IDC-NSTs and from classic ILCs. To define the transcriptomic differences between TCs and IDC-NSTs and ILCs whilst minimizing the impact of histological grade and molecular subtype on their profiles, we subjected a series of grade- and molecular subtype-matched TCs and IDC-NSTs and molecular subtype-matched TCs and classic ILCs to genome-wide gene expression profiling using oligonucleotide microarrays. Unsupervised and supervised analysis ...
Gentaur molecular products has all kinds of products like :search , US Biomax \ Breast invasive ductal carcinoma with matched or unmatched adjacent normal breast tissue array, including TNM and pathology grade, 47cases_80cores, replacing BR802 \ BR802b for more molecular products just contact us
Gentaur molecular products has all kinds of products like :search , US Biomax \ Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 6 cases_24 cores, replacing BR243 \ BR243a for more molecular products just contact us
Myoepithelial cells (MEC) are essential to the maintenance of normal breast function, and loss of normal MEC function is commonly associated with breast cancer. Most established invasive breast carcinomas develop through an in situ phase known as ductal carcinoma in situ (DCIS). We have identified up-regulation of β6 integrin on MEC in a subset of DCIS. Normal MEC exhibit potent tumour suppressor function, but it is not clear whether this is compromised in DCIS. The aim of the present study is to investigate the effect of β6 expression on myoepithelial tumour suppressor function.. Immunohistochemical analysis of DCIS of different grades with and without an invasive breast cancer was carried out to determine the β6 status. For in vitro studies magnetic bead sorting was used to isolate a pure normal-like myoepithelial cell line from the immortalised 1089 cell line (N-1089 MEC). These were used to generate overexpressing myoepithelial cells (DCIS-modified MEC) by β6 retroviral transduction. The ...
Objective: To analyze the type of cancers and high risk lesions diagnosed in women with normal mammograms with dense breasts with the addition of bilateral breast ultrasound and determine whether these lesions make an impact on clinical outcomes.. Methods: Four years of ultrasound data from two sites with five offices in Connecticut was analyzed. The type of lesion including size, nuclear and histologic grade, ER/PR/Her2 status, node status, patient age and risk factors was reviewed.. Results: A total of 532 Ultrasounds with Birads 4 or 5 were reported with 46 cancers or high risk lesions. There were 14 Invasive Ductal Carcinoma, 10 Invasive Lobular Carcinoma, 8 Mixed type, 1 Mucinous, 1 Tubular, 6 Ductal carcinoma in situ, 3 Atypical Ductal Hyperplasia with papilloma and 3 Lobular Carcinoma in situ. Of the invasive cancers and DCIS, 9 were nuclear grade 1, 25 nuclear grade 2 and 7 nuclear grade 3. They ranged in size from .3 to 8 .0 cm and the patient age was 45-77 years. Four patients had ...
Invasive ductal carcinoma (IDC) is the most common form of breast cancer. Find out about IDC symptoms, diagnosis and treatment at Breast Cancer Care.
Hello, I was recently diagnozed with Invasive Ductal Carcinoma. I am 26 years old and this was such a shock to me and my husband. There are really no support groups in my area and I would love to hear from anyone going through this. ------------------------------------------------------------------------ This is an automatically-generated notice. If youd like to be removed from the mailing list, please visit the Medicine-On-Line Discussion Forum at ,http://www.meds.com/con_faq.html,, or send an email message to: [email protected] with the subject line blank and the body of the message containing the line: unsubscribe mol-cancer your-email-address where the phrase your-email-address is replaced with your actual email address ...
Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
At Moffitt Cancer Center, breast cancer research is one of our primary areas of focus. Not only are we looking to determine how ductal carcinoma in situ develops, but also how it can be treated more effectively. For instance, we are studying various hormonal therapies and how they affect hormone receptor-positive cancers, using our laboratory advances to improve outcomes and quality of life for each of our patients.. Our expert oncologists can further explain the causes of ductal carcinoma in situ. To make an appointment, call 1-888-663-3488 or submit a new patient registration form online. No referral is required.. Helpful Links:. ...
While not itself life-threatening, ductal carcinoma in situ (DCIS) can progress to invasive disease if untreated, and confers an increased risk of future breast cancer. We investigated knowledge of DCIS among a cohort of English- and Spanish-speaking Latina and English-speaking non-Latina white women previously treated for DCIS. We examined knowledge of DCIS with four true/false statements about risk of invasive disease, breast cancer recurrence, and prognosis. For each knowledge statement, we modeled the odds of a correct answer by language-ethnicity (English-speaking Latinas, Spanish-speaking Latinas, and English-speaking whites) adjusting for demographics, health history, and treatment factors. Of 710 participants, 52 % were English-speaking whites, 21 % English-speaking Latinas, and 27 % Spanish-speaking Latinas. Less than half (41 %) of participants were aware that DCIS is not life-threatening and only 32 % knew that surgical treatment choice does not impact mortality; whereas two-thirds ...
Hi. I did a search for Ductal Carcinoma and one of the hits was a letter from Jayna. I dont see anything else. Is there a web site I can go to? I would really like to find a lot more information about surgery, therapy and all alternatives. I know I am at the beginning of a long hard journey but I would like to give a little background which may help you point me in the right direction. I am 31 years old and back in August I found a lump. I spoke to my sister and a friend about it and both said wait a week or two to see if it would go away. I was a week away from my period so I waited. It did not go away. I called the OB/GYN and got an appointment for October 12th. I did not tell them about the lump, I guess I still figured it would go away. After I made the appointment I spoke to my mother, a breast cancer survivor twice. I told her the position of the lump and we both agreed that it was strange and would probably be nothing. Let me explain. My mother had breast cancer on the left side 11 years ...
(KudoZ) English to Spanish translation of Metastatic Ductal Carcinoma of the Breast: carcinoma ductal metastásico de mama [Medical (general) (Medical)].
To compare the lesion distribution and the extent of the disease in ductal and lobular carcinomas of the breast, we studied 586 ductal and 133 lobular consecutive cancers. All cases were documented on large-format histology slides. The invasive component of ductal carcinomas was unifocal in 63.3% (371/586), multifocal in 35.5% (208/586), and diffuse in 1.2% (7/586) of the cases. The corresponding figures in the lobular group were 27.8% (37/133), 45.9% (61/586), and 26.3% (35/133), respectively. When the distribution of the in situ and invasive component in the same tumors was combined to give an aggregate pattern, the ductal carcinomas were unifocal in 41.6% (244/586), multifocal in 31.6% (185/586), and diffuse in 26.8% (157/586) of the cases. The corresponding figures in the lobular category were 15.0% (20/133), 54.2% (72/133), and 30.8% (41/133), respectively. Ductal cancers were extensive in 45.7% (268/586), lobular in 65.4% (87/133) of the cases. All these differences were statistically ...
Survivor: Breast Cancer > Invasive (Infiltrating) Ductal Carcinoma Patient Info: Finished active treatment less than 5 years ago, Diagnosed: almost 4 years ago, Female, Age: 47, Stage III, HER2 Positive: No, ER Positive: Yes, PR Positive: Yes
Nearly all women with ductal carcinoma in situ- an early stage of breast cancer- can be successfully treated. Learn about the 2 main subtypes of DCIS.
April 16, 2014 -- Digital mammography finds more small, invasive breast cancers, but it also identifies more ductal carcinoma in situ (DCIS) -- some of which may never cause harm if undetected. But a new study in the April issue of Radiology claims that digital mammography tends to find DCIS lesions that are more likely to progress to cancer. Discuss ...
Population-wide screening with PSA reduces the mortality of prostate cancer (PCa) but with the downside of overdiagnosis and overtreatment [1, 2]. Men considering a PSA test would like to be informed about their benefits, possibilities and extent of overdiagnosis and overtreatment [3]. However, candidates for testing are only willing to accept a small increase of their chance of dying from PCa when considering reducing their chance on overdiagnosis and potential overtreatment [4]. Multivariable risk-based stratification for screening, as put forward by the European Randomized Study of Screening for Prostate Cancer section Rotterdam Risk Calculator (ERSPC-RC), has the potential for informed decision making [5]. But, as stated by Pruthi et al., risk assessment tools do have some shortcomings, which reinforces the need for continuous updating and adaptations of the devices [6]. Within the current study we aimed to improve our ERSPC-RC by incorporating contemporary pathologic biopsy classifications ...
For the first time, scientists have discovered a way to predict whether women with ductal carcinoma in situ (DCIS) - the most common form of non-invasive breast cancer - are at risk of developing more invasive tumors in later ...
Ductal carcinoma in situ (DCIS) is a condition that can sometimes develop into breast cancer. Each year it affects more than 6,300 women in the UK, and thousands more worldwide.. But right now, doctors cant tell whether women with DCIS will go on to develop breast cancer. This means that, unfortunately, some women with DCIS undergo hospital visits, surgery and even chemotherapy and radiotherapy that they dont need, while also causing them unnecessary stress and anxiety.. Dr Jelle Wesseling and his team of scientists from the UK, Netherlands and the US want to change this, and stop women getting treatment they wont benefit from.. The Research. To achieve their aim, Wesselings team will study tissue samples taken from women with DCIS during surgery. These samples will come from women living in the UK, US and the Netherlands.. They will look at these samples in great detail, studying their characteristics, including their genetic make-up and what kind of immune cells they contain. Alongside ...
Here, we show for the first time that dsDNA damage and telomere malfunction in human breast epithelial cells results in a p53- and activin A-dependent COX-2 induction. By identifying signaling events leading to COX-2 induction, this study complements our previous work establishing a direct link between COX-2 and malignant phenotypes (3). Strikingly, COX-2 expression, and its associated phenotypes, are not confined to the initial cell with telomere malfunction, but are also induced in cells in the absence of DNA damage through the cell-nonautonomous action of activin A (Fig. 5D). Although induction of this pathway is self-limiting (i.e., leading to cell cycle arrest) in HMEC (intact p16/Rb pathway), it is not in vHMEC (silenced p16), where cells continue to proliferate. Finally, we show in vivo that high COX-2 expression is associated with high levels of γH2AX, TRF2, and activin A in a pilot cohort of DCIS lesions.. Our study highlights the coordinated action of p53, activin A, and p38 in ...
Mammography is the most common screening examination for breast cancer. A mammogram is surely an x-ray from the breast. This examination might find tumors which have been much too tiny to really feel. A mammogram may also uncover ductal carcinoma in situ (DCIS). In DCIS, youll find abnormal cells while in the lining of a breast duct, which can develop into invasive cancer in a few women ...
I recently was diagnosed with breast cancer...invasive ductal carcinoma. Absolutely no history of this in my family. Could there be a link between all the drugs for ms Ive taken and that?? Ive seen some posts on cop axons and ...
The tumour focus/foci must invade into nonspecialized interlobular or interductal stroma (extension of the lesion beyond the confines of a ductolobular unit, development of a desmoplastic stroma). The cells deemed to be invasive must be distributed in a fashion (non-organoid pattern) that does not represent tangential sectioning of a duct or a lobular structure with in-situ carcinoma. Tangentially sectioned in-situ carcinoma foci that simulate microinvasion are distributed in the specialized periductal and intralobular stroma and usually occur as compact groups of tumour cells that have a smooth border surrounded by a circumferential layer of myoepithelial cells and stroma or a thickened basement membrane (29). At sites of microinvasive foci, tumour cells are distributed singly or as small groups that have irregular shapes reminiscent of conventional invasive carcinoma with no particular orientation (29). There is complete absence of surrounding basement membrane and myoepithelial cells: ...
Greenmedinfo.com - Natural Health Resource - The worlds most widely referenced, open access, natural medicine database, with 30,000+ study abstracts and growing daily
Answers from trusted physicians on what are the treatment options for lcis. First: Lcis is somewhat of a misnomer in that it is not a cancer, but a "pre-malignant" condition in which there are abnormal cells present in the glands (lobules) of the breast. Therefore patients with a diagnosis of lcis are at a higher risk of developing breast cancer than the general population and require closer observation and screening. Hormonal therapy may be used in those with very high risk.
Two tactics have been of inestimable value for observing anatomical changes of the evolving disease: These are (1) serial sectioning and (2) biopsying apparently uninvolved areas of acne-bearing...
Most women with DCIS have no symptoms and are diagnosed through NHS Breast Screening Programmes. A small number of women do have symptoms.
Most women with DCIS have no symptoms and are diagnosed through NHS Breast Screening Programmes. A small number of women do have symptoms.
Sirolimus in Preventing Invasive Breast Cancer in Patients with Ductal Carcinoma In Situ, Lobular Carcinoma In Situ, Atypical Lobular Hyperplasia, or Atypical Ductal Hyperplasia - NCT02642094
Abstract. Lobular carcinoma in situ is a form of in situ neoplasia that develops within the terminal lobules of the breast. It is an extremely rare finding in males due to the lack of lobular development in the male breast. The authors herein report an unusual case of incidentally discovered lobular carcinoma in situ in a male patient with recurrent bilateral gynecomastia who was subsequently diagnosed with invasive ductal carcinoma of the left breast. The pathology of lobular carcinoma in situ in a male as well as screening MRI surveillance of male patients at high risk for breast cancer are discussed, emphasizing the importance of screening and imaging follow up in men who are at high risk for breast cancer.. Keywords: Lobular carcinoma in situ, male, breast cancer, MRI, screening and imaging ...
There is accumulating evidence to suggest that different histological grades of invasive ductal breast carcinomas may have distinct molecular origins and pathogenesis and do not typically progress from one grade group to another (28, 29, 30, 31) . The different grades have different clinical behaviors, and within-grade studies to identify the more aggressive subgroups of these classes of breast tumors would be of great assistance in clinical management. The expression of basal/myoepithelial markers has been observed in a proportion of grade III invasive breast tumors, and the spectrum of basal-like tumors, also recognized by morphology (15 , 32) , molecular cytogenetics (16 , 33) , and expression profiling (18 , 19) , has been associated with poor prognosis (17) . CGH has the advantage of being applied to archival pathology specimens with long-term follow-up as well as being amenable to microdissection strategies to profile the molecular genetic change occurring in a pure population of tumor ...
Objective:. The role of axillary staging and natural history in microinvasive breast cancer (MIC) is not well known. This study assesses outcome in patients with ductal carcinoma in situ (DCIS) with microinvasion who did not undergo sentinel lymph node biopsy (SNB).. Methods:. A retrospective analysis of DCIS with microinvasion (DCISM) patients surgically treated at the Asan Medical Center from March, 2003 to December, 2009 was conducted. Bilateral breast cancer patients and patients who underwent node dissection were excluded from the study. SNB was performed in most of DCIS patients after surgery when microinvasion was found, but in some patients with clinically negative axillary lymph node metastasis, SNB was omitted.. Results:. A total of 185 consecutive patients with DCISM were identified. Thirty-three patients did not undergo SNB [SNB(-) group], while 152 patients did [SNB(+) group]. No recurrence occurred in the SNB(-) group during a median follow-up period of 63.5 months, while one ...
ReportsnReports.com adds report Global Breast Cancer Market 2014-2018 to its store. Breast cancer is characterized by the uncontrolled growth of cancerous cells in the breast tissue. It occurs in both males and females; however, male breast cancer is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer and other undifferentiated carcinoma. Ductal carcinoma is the form of breast cancer which starts in the lining of the milk ducts while lobular carcinoma begins in the milk glands of the breast. When breast cancer spreads from the site of origin to surrounding tissue, it is known as invasive breast cancer. Invasive ductal carcinoma is the most common subtype accounting for 70 to 80 percent of all the breast cases. In women, breast cancer is the second most common form of cancer. GLOBOCAN reported that in the year 2012, breast cancer accounted for 11.9 percent of the total cancer cases and lead to 5,22,000 deaths worldwide.. Analysts forecast ...
Lebanon, NH. While doctors almost always agree on a pathological diagnosis of invasive breast cancer, there is room for improvement when diagnosing atypia (or atypical ductal hyperplasia-ADH) and DCIS (ductal carcinoma in-situ), Anna Tosteson, ScD and Tracy Onega, PhD from Dartmouth-Hitchcocks Norris Cotton Cancer Center have found. The Dartmouth investigators, and national collaborators, published the study, Diagnostic Concordance Among Pathologists Interpreting Breast Biopsy Specimens, today in JAMA.. About 1.6 million breast biopsies are done every year in the U.S., yet in nearly half of the cases labeled atypia, our study indicates that there simply isnt concordance, meaning there is not agreement with a standard reference diagnosis, explained Tosteson. In the study, a panel of three expert pathologists determined the reference diagnosis for each of 240 cases that included 23 cases of invasive breast cancer, 73 DCIS, 72 with atypical hyperplasia (atypia), and 72 benign cases without ...

Carcinoma, Intraductal, Noninfiltrating - Medical DictionaryCarcinoma, Intraductal, Noninfiltrating - Medical Dictionary

define Carcinoma, Intraductal, Noninfiltrating. Explain Carcinoma, Intraductal, Noninfiltrating. What is Carcinoma, Intraductal ... Carcinoma, Intraductal, Noninfiltrating. Medical Dictionary -> Carcinoma, Intraductal, Noninfiltrating. Search: Carcinoma, ... Intraductal, Noninfiltrating. A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of ... Noninfiltrating? Carcinoma, Intraductal, Noninfiltrating FAQ. ...
more infohttp://medicaldictionaryweb.com/Carcinoma,+Intraductal,+Noninfiltrating-definition/

Paul E Gosss Research on letrozole (Femara)
     | CureHunterPaul E Goss's Research on letrozole (Femara) | CureHunter

Noninfiltrating Intraductal Carcinoma (DCIS) 06/2011 - 01/2002. 2. Arthritis (Polyarthritis) 04/2008 - 11/2003. ...
more infohttp://www.curehunter.com/public/authorSummary-Goss,%20Paul%20E.do?keywordId=C067431

Beat Thürlimanns Research on letrozole (Femara)
     | CureHunterBeat Thürlimann's Research on letrozole (Femara) | CureHunter

Noninfiltrating Intraductal Carcinoma (DCIS) 09/2003. Drug/Important Bio-Agent (IBA). 25. TamoxifenFDA LinkGeneric 12/2015 - 09 ... Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.. ...
more infohttp://www.curehunter.com/public/authorSummary-Th%C3%BCrlimann,%20Beat.do?keywordId=C067431

Breast Cancer and the Obstetrician-Gynecologist | GLOWMBreast Cancer and the Obstetrician-Gynecologist | GLOWM

Intraductal carcinoma and lobular carcinoma in situ. Intraductal carcinoma, noninfiltrating, NOS. Lobular carcinoma in situ, ... Lobular carcinoma in situ (LCIS) is thought to be a tumor marker with associated increased risk of eventual invasive carcinoma ... DUCTAL CARCINOMA IN SITU. Ductal carcinoma in situ (DCIS) is a heterogeneous disease, in terms of its radiological ... Invasive lobular carcinoma spreads diffusely with a typical histologic Indian file pattern. Thus, invasive lobular carcinoma is ...
more infohttp://www.glowm.com/section_view/item/16/recordset/71685/value/16

A case report of primary small cell carcinoma of the breast and review of the literature.A case report of primary small cell carcinoma of the breast and review of the literature.

Primary small cell carcinoma (SCC) of the breast, an exceedingly rare and aggressive tumor, is often characterized by rapid ... Carcinoma, Intraductal, Noninfiltrating / drug therapy, metabolism, pathology, radiography, ultrasonography. Carcinoma, Small ... Primary small cell carcinoma (SCC) of the breast is a subtype of neuroendocrine carcinoma. Wade et al.[1] described the first ... Primary small cell carcinoma of the breast with TTF-1 and neuroendocrine marker expressing carcinoma in situInt J Clin Exp ...
more infohttp://www.biomedsearch.com/nih/case-report-primary-small-cell/22516480.html

Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score. - NextBio...Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score. - NextBio...

Carcinoma, Intraductal, Noninfiltrating Female Humans Middle Aged Mitotic Index Neoplasm Recurrence, Local Receptors, Estrogen ... with mitotic count in ductal carcinoma in situ (≤ 1 vs >1) and dense chronic inflammation around ductal carcinoma in situ one ... The Oncotype DX Breast Cancer Assay for ductal carcinoma in situ is used to determine local recurrence risk in patients with ... Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score. Adriana ...
more infohttp://www.nextbio.com/b/search/article.nb?id=26111975

Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer - Full Text View -...Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer - Full Text View -...

Carcinoma. Breast Neoplasms. Carcinoma in Situ. Carcinoma, Ductal. Carcinoma, Intraductal, Noninfiltrating. Neoplasms, ... Breast Carcinoma In Situ. Oxytocin. Oxytocics. Reproductive Control Agents. Physiological Effects of Drugs. ... Breast Cancer Ductal Carcinoma in Situ Drug: Intranasal Oxytocin Early Phase 1 ... Identifying the miR Fingerprint in NAF, Serum, and Tissue in Patients With Ductal Carcinoma in Situ (DCIS) or Invasive Breast ...
more infohttps://clinicaltrials.gov/ct2/show/study/NCT02127073

Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer - Full Text View -...Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer - Full Text View -...

Carcinoma. Breast Neoplasms. Carcinoma in Situ. Carcinoma, Ductal. Carcinoma, Intraductal, Noninfiltrating. Neoplasms, ... Breast Carcinoma In Situ. Oxytocin. Oxytocics. Reproductive Control Agents. Physiological Effects of Drugs. ... Breast Cancer Ductal Carcinoma in Situ Drug: Intranasal Oxytocin Early Phase 1 ... Identifying the miR Fingerprint in NAF, Serum, and Tissue in Patients With Ductal Carcinoma in Situ (DCIS) or Invasive Breast ...
more infohttps://clinicaltrials.gov/ct2/show/NCT02127073?term=breast+AND+neoplasms&lup_s=04%2F08%2F2014&lup_d=30

Attenuated podoplanin staining in breast myoepithelial cells: A potential caveat in the diagnosis of lymphatic invasion<...Attenuated podoplanin staining in breast myoepithelial cells: A potential caveat in the diagnosis of lymphatic invasion<...

Carcinoma, Intraductal, Noninfiltrating Epithelium Neoplasms Breast Neoplasms All Science Journal Classification (ASJC) codes. ... ME cells surrounding ductal carcinoma in situ (DCIS) displayed weaker (1+ to 2+) podoplanin expression with 26 (72%) foci ... ME cells surrounding ductal carcinoma in situ (DCIS) displayed weaker (1+ to 2+) podoplanin expression with 26 (72{\%}) foci ... ME cells surrounding ductal carcinoma in situ (DCIS) displayed weaker (1+ to 2+) podoplanin expression with 26 (72%) foci ...
more infohttps://pennstate.pure.elsevier.com/en/publications/attenuated-podoplanin-staining-in-breast-myoepithelial-cells-a-po

Clinicopathologic features of breast cancers that develop in women with previous benign breast disease<...Clinicopathologic features of breast cancers that develop in women with previous benign breast disease<...

Cancer characteristics were similar across the 3 histologic categories of BBD, with a similar frequency of ductal carcinoma in ... Cancer characteristics were similar across the 3 histologic categories of BBD, with a similar frequency of ductal carcinoma in ... Cancer characteristics were similar across the 3 histologic categories of BBD, with a similar frequency of ductal carcinoma in ... Cancer characteristics were similar across the 3 histologic categories of BBD, with a similar frequency of ductal carcinoma in ...
more infohttps://jhu.pure.elsevier.com/en/publications/clinicopathologic-features-of-breast-cancers-that-develop-in-wome

Evaluation of survivin immunoexpression in the differentiation of high- and low-grade breast ductal carcinoma in situEvaluation of survivin immunoexpression in the differentiation of high- and low-grade breast ductal carcinoma in situ

Keywords Inhibitor of apoptosis proteins; Carcinoma, intraductal, noninfiltrating; Biomarkers, tumor; Neoplasm proteins; Breast ... Descritores Proteínas inibidoras de apoptose; Carcinoma intraductal não infiltrante; Biomarcadores tumorais; Proteínas de ... formado por mulheres com carcinoma ductal in situ de baixo grau; e Grupo B, por mulheres com carcinoma ductal in situ de alto ... composed of women with low-grade ductal carcinoma in situ, and Group B, women with high-grade ductal carcinoma in situ. ...
more infohttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082018000100201

adenoma of nipple 2005:2010[pubdate] *count=100 - BioMedLib™ search engineadenoma of nipple 2005:2010[pubdate] *count=100 - BioMedLib™ search engine

Carcinoma, Intraductal, Noninfiltrating / pathology. Nipples / pathology. *[Email] Email this result item Email the results to ... well differentiated papillary carcinoma, invasive lobular carcinoma, and tubular carcinoma) to a false negative. ... Important differential diagnosis include nipple adenoma, tubular carcinoma and adenosquamous carcinoma.. *[MeSH-major] Adenoma ... Histopathologically, it must be distinguished from florid papillomatosis, adenosquamous carcinoma, adenoid cystic carcinoma and ...
more infohttp://www.bmlsearch.com/?kwr=adenoma+of+nipple+2005:2010%5Bpubdate%5D&cxts=100&stmp=b0

Hypermethylation of 14-3-3 σ (stratifin) is an early event in breast cancer<...Hypermethylation of 14-3-3 σ (stratifin) is an early event in breast cancer<...

Carcinoma, Intraductal, Noninfiltrating Carcinogenesis Carcinoma Keywords. *14-3-3 σ. *Breast cancer ... We found hypermethylation of σ in 24 of 25 carcinomas (96%), 15 of 18 (83%) of ductal carcinoma in situ, and three of eight (38 ... We found hypermethylation of σ in 24 of 25 carcinomas (96%), 15 of 18 (83%) of ductal carcinoma in situ, and three of eight (38 ... We found hypermethylation of σ in 24 of 25 carcinomas (96%), 15 of 18 (83%) of ductal carcinoma in situ, and three of eight (38 ...
more infohttps://jhu.pure.elsevier.com/en/publications/hypermethylation-of-14-3-3-%CF%83-stratifin-is-an-early-event-in-breas-3

Gregg, J.<...Gregg, J.<...

Carcinoma, Intraductal, Noninfiltrating Medicine & Life Sciences * Circulating Tumor DNA Medicine & Life Sciences ... MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC ...
more infohttps://ucdavis.pure.elsevier.com/en/persons/jeffrey-gregg

A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease<...A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease<...

A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease. / Jakub, James W; Murphy, Brittany L ... A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease. In: Annals of Surgical Oncology. ... A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease. Annals of Surgical Oncology. 2017 ... Background: Approximately 8-56% of patients with a core needle biopsy (CNB) diagnosis of ductal carcinoma in situ (DCIS) will ...
more infohttps://mayoclinic.pure.elsevier.com/en/publications/a-validated-nomogram-to-predict-upstaging-of-ductal-carcinoma-in-

Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS - Full Text View - ClinicalTrials...Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS - Full Text View - ClinicalTrials...

Carcinoma in Situ. Carcinoma, Ductal. Carcinoma, Intraductal, Noninfiltrating. Carcinoma. Neoplasms, Glandular and Epithelial. ... DCIS Ductal Carcinoma in Situ Other: Guideline Concordant Care Other: Active Surveillance Not Applicable ... Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002 Oct 16;94(20):1546-54 ... Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast ...
more infohttps://www.clinicaltrials.gov/ct2/show/NCT02926911?term=02926911&rank=1

Surgery, Breast Surgery Division - Fingerprint
     - Northwestern ScholarsSurgery, Breast Surgery Division - Fingerprint - Northwestern Scholars

Carcinoma, Intraductal, Noninfiltrating * Mastectomy * Mammaplasty * Neoplasm Metastasis * Sentinel Lymph Node * Segmental ...
more infohttps://www.scholars.northwestern.edu/en/organisations/surgery-breast-surgery-division/fingerprints/

Luis Zabala Blanco Jr - Research Output
     - Northwestern ScholarsLuis Zabala Blanco Jr - Research Output - Northwestern Scholars

Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting analysis ... The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast. Ubago, J. M., Blanco, L. Z., Shen, T. & Siziopikou ... Multinucleation is an objective feature useful in the diagnosis of pleomorphic lobular carcinoma in situ. Blanco, L. Z., Thurow ... Ovarian Carcinosarcoma and Concurrent Serous Tubal Intraepithelial Carcinoma With Next-Generation Sequencing Suggesting an ...
more infohttps://www.scholars.northwestern.edu/en/persons/luis-zabala-blanco-jr/publications/?ordering=type&descending=false

Rafael Fonseca, MD - Research Output
     - Mayo ClinicRafael Fonseca, MD - Research Output - Mayo Clinic

Ductal carcinoma in situ of the breast. Fonseca, R., Hartmann, L. C., Petersen, I. A., Donohue, J. H., Crotty, T. B. & Gisvold ...
more infohttps://mayoclinic.pure.elsevier.com/en/persons/rafael-fonseca/publications/?page=2&ordering=type&descending=false

US8642269B2 - Detection of nucleic acid sequence differences using coupled polymerase chain reactions 
        - Google PatentsUS8642269B2 - Detection of nucleic acid sequence differences using coupled polymerase chain reactions - Google Patents

208000010027 Carcinoma, Intraductal, Noninfiltrating Diseases 0 description 1 * 208000008761 Central Nervous System Neoplasms ... 206010073094 Intraductal proliferative breast lesion Diseases 0 description 1 * 201000008166 Kennedys diseases Diseases 0 ... 201000000498 stomach carcinoma Diseases 0 description 2 * JNEZJAAADKQBBD-UHFFFAOYSA-N tris(2-chlorophenyl) borate Chemical ...
more infohttps://patents.google.com/patent/US8642269B2/en

E LEUSCHNER | Researcher Profile | Symptoma.comE LEUSCHNER | Researcher Profile | Symptoma.com

Carcinoma, Intraductal, Noninfiltrating ❗ Check More at Symptoma.com ... Carcinoma, Intraductal, Noninfiltrating 1x. Brain Neoplasms 1x. Carcinoma, Medullary 1x. Fibroadenoma 1x. Head and Neck ...
more infohttps://www.symptoma.com/en/research/profile/e_leuschner

Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ<...Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ<...

Carcinoma, Intraductal, Noninfiltrating, Disease Progression, Female, Humans, Middle Aged, Neoplasm Grading, Neoplasm ... Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. In: European Journal of Surgical ... Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. European Journal of Surgical ... Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. / Maxwell, Anthony J; Clements, ...
more infohttps://abdn.pure.elsevier.com/en/publications/risk-factors-for-the-development-of-invasive-cancer-in-unresected

Find Research Outputs
             - Kyushu UniversityFind Research Outputs - Kyushu University

A case report of total remnant pancreatectomy for ductal carcinoma after distal pancreatectomy for invasive intraductal ... A case of hepatic resection of liver metastasis 8 years after resection of an adenoid cystic carcinoma of the parotid gland].. ... A case of massive hepatocellular carcinoma producing various imaging patterns after long-term follow-up].. Wada, A., Hama, N., ... A case of advanced hepatocellular carcinoma with tumor thrombosis in the main trunk of the portal vein successfully treated by ...
more infohttps://kyushu-u.pure.elsevier.com/en/publications/?ordering=title&descending=false&showAdvanced=false&allConcepts=true&inferConcepts=true&publicationYear=2011&publicationYear=2012&publicationYear=2013&publicationYear=2014&publicationYear=2015&publicationYear=2016&publicationYear=2017&publicationYear=2018&publicationYear=2019&publicationYear=2020&author=cc9b53e7-0ee2-4cba-88c0-1fa666e98ff6
  • Primary small cell carcinoma (SCC) of the breast, an exceedingly rare and aggressive tumor, is often characterized by rapid progression and poor prognosis. (biomedsearch.com)
  • A case of advanced hepatocellular carcinoma with inferior vena cava tumor thrombus and multiple intrahepatic metastases treated successfully by transcatheter arterial chemoembolization and radical hepatectomy]. (elsevier.com)
  • A case of advanced hepatocellular carcinoma with tumor thrombosis in the main trunk of the portal vein successfully treated by multidisciplinary therapies]. (elsevier.com)
  • A case of successful second look operation for hepatocellular carcinoma with right atrial tumor thrombus]. (elsevier.com)
  • Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. (curehunter.com)
  • A case of hepatic resection of liver metastasis 8 years after resection of an adenoid cystic carcinoma of the parotid gland]. (elsevier.com)
  • A case of a patient with hepatocellular carcinoma who achieved long-term survival after repeated transcatheter arterial chemoembolization and sorafenib therapy]. (elsevier.com)
  • A case of complete response to interferon-α and S-1 combination therapy for multiple pulmonary recurrences of hepatocellular carcinoma after hepatic resection]. (elsevier.com)